Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Puma Biotechnology (PBYI) Work In Process: 2020-2025

Historic Work In Process for Puma Biotechnology (PBYI) over the last 4 years, with Sep 2025 value amounting to $5.4 million.

  • Puma Biotechnology's Work In Process rose 169.08% to $5.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.4 million, marking a year-over-year increase of 169.08%. This contributed to the annual value of $758,000 for FY2024, which is 7.56% down from last year.
  • Per Puma Biotechnology's latest filing, its Work In Process stood at $5.4 million for Q3 2025, which was up 305.94% from $1.3 million recorded in Q2 2025.
  • In the past 5 years, Puma Biotechnology's Work In Process ranged from a high of $7.8 million in Q2 2024 and a low of $758,000 during Q4 2024.
  • Over the past 3 years, Puma Biotechnology's median Work In Process value was $2.0 million (recorded in 2024), while the average stood at $2.7 million.
  • Within the past 5 years, the most significant YoY rise in Puma Biotechnology's Work In Process was 169.08% (2025), while the steepest drop was 82.89% (2025).
  • Puma Biotechnology's Work In Process (Quarterly) stood at $1.4 million in 2021, then surged by 92.13% to $2.7 million in 2022, then plummeted by 69.18% to $820,000 in 2023, then decreased by 7.56% to $758,000 in 2024, then surged by 169.08% to $5.4 million in 2025.
  • Its last three reported values are $5.4 million in Q3 2025, $1.3 million for Q2 2025, and $1.1 million during Q1 2025.